Showing 901 - 920 results of 980 for search '"Philadelphia"', query time: 0.06s Refine Results
  1. 901

    Improved Patient Outcomes by Normalizing Sympathovagal Balance: Differentiating Syncope—Precise Subtype Differentiation Leads to Improved Outcomes by Nicholas L. DePace, Julie A. Bateman, Michael Yayac, John Oh, Mushfiqur Siddique, Cesar Acosta, Jeysel M. Pinales, Aaron I. Vinik, Heather L. Bloom

    Published 2018-01-01
    “…P&S monitoring (ANSAR, Inc., Philadelphia, PA) differentiates subtypes in 2727 cardiology patients (50.5% female; average age: 57 years; age range: 12–100 years), serially tested over four years (3.3 tests per patient, average). …”
    Get full text
    Article
  2. 902
  3. 903
  4. 904
  5. 905
  6. 906
  7. 907
  8. 908
  9. 909
  10. 910
  11. 911
  12. 912
  13. 913
  14. 914
  15. 915
  16. 916

    Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States by Finn RS, Iyer R, Kalman RS, Parikh ND, Cabrera R, Babajanyan S, Kaseb AO

    Published 2025-02-01
    “…Richard S Finn,1 Renuka Iyer,2 Richard S Kalman,3 Neehar D Parikh,4 Roniel Cabrera,5 Svetlana Babajanyan,6 Ahmed O Kaseb7 1Department of Medicine, University of California, Los Angeles, CA, USA; 2Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA; 3Department of Medicine, Einstein Medical Center, Philadelphia, PA, USA; 4Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA; 5Department of Medicine, University of Florida Health, Gainesville, FL, USA; 6US Medical Affairs, Oncology, Bayer Healthcare, Whippany, NJ, USA; 7Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence: Richard S Finn, Department of Medicine, University of California, Los Angeles, CA, USA, Tel +1-310-586-2091, Email rfinn@mednet.ucla.eduIntroduction: While several systemic therapies are available for unresectable hepatocellular carcinoma (uHCC), there is a lack of granular real-world evidence to support the efficacy and safety of these therapies. …”
    Get full text
    Article
  17. 917

    Preferences and Attitudes Towards Digital Communication and Symptom Reporting Methods in Clinical Trials by McDowell B, Dumais KM, Gary ST, de Gooijer I, Ward T

    Published 2025-01-01
    “…Bryan McDowell,1 Kelly M Dumais,2 Sarah Tressel Gary,2 Ingeborg de Gooijer,2 Tomás Ward3 1eCOA Science, Clario, Geneva, Switzerland; 2eCOA Science, Clario, Philadelphia, PA, USA; 3Insight Science Foundation Ireland Research Centre for Data Analytics, Dublin City University, Dublin, IrelandCorrespondence: Bryan McDowell, eCOA Science, Clario, Chemin Louis-Hubert 2, Petit-Lancy, Geneva, 1213, Switzerland, Tel +41 22 879 91 00, Fax +41 22 879 91 01, Email bryan.mcdowell@clario.comPurpose: With the growing use of digital health technologies (DHT) in clinical trials, the opportunity to use technology to promote greater patient centricity and inclusivity has emerged. …”
    Get full text
    Article
  18. 918
  19. 919
  20. 920